Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07075718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 82% 610 → 110 participants
See other at-risk trials from Glaukos Corporation

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 610 → 110 participants Show 4 more changesShow less
    • Phase changed: Phase 2/3 → Phase 2
    • Trial arms changed: 9 → 3
    • Eligibility criteria expanded, about 4 words
    • Study title shortened, about 1 word
  2. Re-verified, no change to tracked fieldsv4
  3. Site contacts updated at 3 of 3 sitesv3
  4. Eligibility criteria expanded, about 6 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Trial Details
NCT Number NCT07075718
Lead Sponsor Glaukos Corporation
Conditions
(from sponsor)		 Glaucoma
Related terms Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov